Skip to content

uniQure QURE Earnings yield

Earnings yield at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-4%-4.3pp
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
-10.1%-4.0pp
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
-16.7%-3.6pp
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-8.8%-22.8pp
Precigen logo
PrecigenPGEN
-14.9%-5.5pp
PTC Therapeutics logo
PTC TherapeuticsPTCT
15.4%+10.2pp

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Calculated from uniQure’s reported figures.

Based on trailing twelve months.

The official record: uniQure’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's earnings yield?
uniQure (QURE) reported earnings yield of -20.4% in Q1 2026.
How has uniQure's earnings yield changed year-over-year?
uniQure's earnings yield increased by 46.2% year-over-year, from -38% to -20.4%.
What is the long-term trend for uniQure's earnings yield?
Over 5 years (2020 to 2025), uniQure's earnings yield has grown at a 12.3% compound annual growth rate (CAGR), from -7.5% to -13.3%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.